Olorinab
Olorinab (APD371) is a drug being developed by Arena Pharmaceuticals for the treatment of gastrointestinal pain associated with Crohn's disease and irritable bowel syndrome.[1] It acts as a potent and selective cannabinoid CB2 receptor agonist and is claimed to be orally active and peripherally selective.[2][3] Initial Phase IIa exploratory clinical trials have been successful,[4] with Phase IIb trials projected to start in 2019.[5]
Clinical data | |
---|---|
Routes of administration | Oral |
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
KEGG | |
Chemical and physical data | |
Formula | C18H24N5O3 |
Molar mass | 358.422 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
|
See also
- MDMB-FUBINACA (similar structure but agonist at both CB1 and CB2 receptors)
- NESS-040C5
- Tedalinab
References
- "Arena Pharmaceuticals Presented New Phase 2 Data for Etrasimod and Olorinab at the 14th Congress of European Crohn's and Colitis Organisation". Arena Pharmaceuticals, Inc. Retrieved 2019-04-13.
- Han S, Thoresen L, Jung JK, Zhu X, Thatte J, Solomon M, et al. (December 2017). "Discovery of APD371: Identification of a Highly Potent and Selective CB2 Agonist for the Treatment of Chronic Pain". ACS Medicinal Chemistry Letters. 8 (12): 1309–1313. doi:10.1021/acsmedchemlett.7b00396. PMC 5733264. PMID 29259753.
- "Olorinab (APD371)". Arena Pharmaceuticals, Inc.
- "Arena Pharmaceuticals Reports Positive Phase 2a Results for Olorinab in Patients with Abdominal Pain Associated with Crohn's Disease". Arena Pharmaceuticals, Inc. Retrieved 2019-04-13.
- "18th Annual Needham Healthcare Conference". wsw.com. Retrieved 2019-04-13.
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.